Modification of multiple sclerosis phenotypes by african ancestry at HLA

Archives of Neurology

Volumn 66, Issue 2, 2009, Pages 226-233

  Cree, Bruce A C ^a,g   Reich, David E ^b   Khan, Omar ^c   De Jager, Philip L ^d   Nakashima, Ichiro ^e,f   Takahashi, Toshiyuki ^e   Bar Or, Amit ^f   Tong, Christine ^a   Hauser, Stephen L ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f MCGILL UNIVERSITY   (Canada)

^g UCSF Multiple Sclerosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPENDENT PERSONALITY DISORDER; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; PHENOTYPE; POPULATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SPINE DISEASE; STATISTICAL SIGNIFICANCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HLA ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 60549096301     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.541     Document Type: Article

References (42)

1. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler. 2003;9(3):293-298.
2. Buchanan RJ, Martin RA, Zuniga M, et al. Nursing home residents with multiple sclerosis: comparisons of African American residents to white residents at admission. Mult Scler. 2004;10(6):660-667.
3. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11): 2039-2045.
4. Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006; 12(6):775-781.
5. Marrie RA, Cutter G, Tyry T, et al. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66(8):1235-1240.
6. Buchanan RJ, Martin RA, Wang S, et al. Racial analyses of longer-stay nursing home residents with multiple sclerosis. Ethn Dis. 2006;16(1):159-165.
7. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain. 2002;125(pt 1):150-158.
8. Brassat D, Azais-Vuillemin C, Yaouanq J, et al. Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. Neurology. 1999;52(8):1632-1636.
9. Hensiek AE, Sawcer SJ, Feakes R, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72(2):184-187.
10. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003;72(3):710-716.
11. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology. 2007;68(5):376-383.
12. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A. 2007;104(52):20896-20901.
13. The International Multiple Sclerosis Genetics Consortium; SawcerS, Ban M, Ma- ranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77(3):454-467.
14. The International Multiple Sclerosis Genetics Consortium; Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-862.
15. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004;74 (1):160-167.
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
17. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005; 64(7):1144-1151.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444- 1452.
19. US Department of Commerce. Profiles of General Characteristics: 2000 Census of Population and Housing. http://www.census.gov/prod/cen2000/dp1/2kh00. pdf. Issued May 2001; Accessed October 1, 2008.
20. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007;68(5):326-337.
21. Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans, 1: race, sex, and geographic distribution. Neurology. 1979;29(9, pt 1):1228-1235.
22. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol. 2004;55(1):65-71.
23. Patterson N, Hattangadi N, Lane B, et al. Methods for high-density admixture mapping of disease genes. Am J Hum Genet. 2004;74(5):979-1000.
24. Reich D, Patterson N, De Jager PL, et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet. 2005;37(10):1113-1118.
25. Simon K, Yang X, Munger KL, et al. Variation in the Epstein-Barr virus receptor, CR2, and risk of multiple sclerosis. Mult Scler. 2007;13(7):947-948.
26. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364 (9451):2106-2112.
27. Lennon VA, KryzerTJ, Pittock SJ, et al. IgG markerof optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.
28. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med. 2006;210(4):307-313.
29. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130(pt 5):1235-1243.
30. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
31. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114.
32. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813-2824.
33. Seldin MF. Admixture mapping as a tool in gene discovery. Curr Opin Genet Dev. 2007;17(3):177-181.
34. Fukazawa T, Kikuchi S, Sasaki H, et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1*0501 allele. J Neurol. 2000;247(3):175-178.
35. Fukazawa T, Kikuchi S, Miyagishi R, et al. HLA-dPB1*0501 is not uniquely associated with opticospinal multiple sclerosis in Japanese patients: important role of DPB1*0301. Mult Scler. 2006;12(1):19-23.
36. Gregersen JW, Kranc KR, Ke X, et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature. 2006;443(7111):574-577.
37. Yeo TW, De Jager PL, Gregory SG, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol. 2007;61(3):228-236.
38. de Jong BA, Huizinga TW, Zanelli E, et al. Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology. 2002;59 (4):549-555.
39. Masterman T, Ligers A, Olsson T, et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000;48(2):211-219.
40. Celius EG, Harbo HF, Egeland T, et al. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000;178(2):132-135.
41. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2008;28(1):17-28.
42. Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887-895.